Back

Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric CNS tumors

Corbett, R. J.; Kaufman, R. S.; McQuaid, S. W.; Vaksman, Z.; Phul, S.; Brown, M. A.; Mason, J. L.; Waszak, S. M.; Zhang, B.; Zhong, C.; Desai, H.; Hausler, R.; Naqvi, A. S.; Chroni, A.; Geng, Z.; Gonzalez, E. M.; Zhu, Y.; Heath, A. P.; Li, M.; Penn Medicine BioBank, ; Regeneron Genetics Center, ; Storm, P. B.; Resnick, A. C.; Maxwell, K. N.; Cole, K. A.; Waanders, A. J.; Bornhorst, M.; MacFarland, S. P.; Rokita, J. L.; Diskin, S. J.

2025-02-06 oncology
10.1101/2025.02.04.25321499 medRxiv
Show abstract

The contribution of rare pathogenic/likely pathogenic (P/LP) germline variants to pediatric central nervous system (CNS) tumor development remains understudied. Here, we characterized the prevalence and clinical significance of germline P/LP variants in cancer predisposition genes across 830 CNS tumor patients from the Pediatric Brain Tumor Atlas (PBTA). We identified germline P/LP variants in 23.3% (193/830) of patients and the majority (137/193) lacked clinical reporting of genetic tumor syndromes. Among P/LP carriers, 34.6% had putative somatic second hits or loss of function tumor alterations. Finally, we linked pathogenic germline variation with novel somatic events and patient survival to highlight the impact of germline variation on tumorigenesis and patient outcomes.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.